Correction to: Decitabine/Cedazuridine: First Approval.
作者信息
Dhillon Sohita
机构信息
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
出版信息
Drugs. 2021 Jan;81(1):179. doi: 10.1007/s40265-020-01453-2.
Abstract
摘要
相似文献
1
Correction to: Decitabine/Cedazuridine: First Approval.对《地西他滨/西扎珠苷：首次批准》的勘误
Drugs. 2021 Jan;81(1):179. doi: 10.1007/s40265-020-01453-2.
2
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.地西他滨与西扎珠苷口服固定剂量复方制剂治疗骨髓增生异常综合征：一项多中心、开放标签、剂量递增的1期研究。
Lancet Haematol. 2019 Apr;6(4):e194-e203. doi: 10.1016/S2352-3026(19)30030-4.
4
Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model.口服阿扎胞苷和 Cedazuridine 近似于注射用阿扎胞苷在小鼠模型中的疗效。
Target Oncol. 2020 Apr;15(2):231-240. doi: 10.1007/s11523-020-00709-x.
5
Decitabine treatment of patients with higher-risk myelodysplastic syndromes.地西他滨治疗高危骨髓增生异常综合征患者。
Leuk Res. 2009 Dec;33 Suppl 2:S12-7. doi: 10.1016/S0145-2126(09)70228-0.
6
Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.美国老年慢性粒单核细胞白血病患者的低甲基化药物治疗与生存情况：一项基于大规模人群的研究
Cancer. 2017 Oct 1;123(19):3754-3762. doi: 10.1002/cncr.30814. Epub 2017 Jun 16.
7
The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.欧洲药品管理局对用于治疗成年急性髓系白血病患者的地西他滨（达珂）的审评：人用药品委员会科学评估总结
Oncologist. 2016 Jun;21(6):692-700. doi: 10.1634/theoncologist.2015-0298. Epub 2016 Apr 18.
8
Decitabine.地西他滨
Recent Results Cancer Res. 2014;201:269-97. doi: 10.1007/978-3-642-54490-3_18.
9
Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716.地西他滨：2'-脱氧-5-氮杂胞苷、阿扎胞苷、DAC、地西他滨、NSC 127716 。
Drugs R D. 2003;4(6):352-8. doi: 10.2165/00126839-200304060-00004.
10
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.地西他滨（一种去甲基化剂）在慢性粒单核细胞白血病中的活性。
Cancer. 2007 Feb 15;109(4):713-7. doi: 10.1002/cncr.22457.
引用本文的文献
1
The combination of decitabine with multi-omics confirms the regulatory pattern of the correlation between DNA methylation of the CACNA1C gene and atrial fibrillation.地西他滨与多组学相结合证实了CACNA1C基因DNA甲基化与心房颤动之间相关性的调控模式。
Front Pharmacol. 2024 Dec 13;15:1497977. doi: 10.3389/fphar.2024.1497977. eCollection 2024.
2
Decitabine suppresses MDSC-induced immunosuppression through dual functional mechanism and inhibits melanoma metastasis.地西他滨通过双重功能机制抑制 MDSC 诱导的免疫抑制作用，并抑制黑色素瘤转移。
Med Oncol. 2024 May 31;41(7):165. doi: 10.1007/s12032-024-02320-w.
3
The role of aberrant DNA methylation in cancer initiation and clinical impacts.异常DNA甲基化在癌症发生及临床影响中的作用。
Ther Adv Med Oncol. 2024 Jan 28;16:17588359231220511. doi: 10.1177/17588359231220511. eCollection 2024.
4
Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating Agents.氮杂核苷类似物作为DNA去甲基化剂的治疗应用
Epigenomes. 2023 Jul 5;7(3):12. doi: 10.3390/epigenomes7030012.
Zotero 插件